Gonorrhea
Drug research and approvals for gonorrhea: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 20, 2026, 19 studies of gonorrhea are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 19
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Factors Associated With Positive Post-Treatment STI Tests and Sexual Knowledge, Attitudes, Behaviors and PracticesNCT07936214 · Not applicable · Centre Hospitalier de Martigues · starts Oct 29, 2026
- Safety and Immunogenicity Study of a Multivalent Gonorrhoea VaccineNCT07758972 · Phase 1 · LimmaTech Biologics AG · starts Aug 19, 2026
- 500-mg Versus 1000-mg Ceftriaxone for Uncomplicated Gonorrhea InfectionNCT07710118 · Phase 3 · National Taiwan University Hospital · starts Jul 1, 2026
- A Study to Evaluate the Performance, Usability, and Contrived Result Interpretation of iStatis Gonorrhea Antigen TestNCT07569900 · Not applicable · bioLytical Laboratories · starts Nov 26, 2025
- Performance, Acceptability, and Usability of a Novel Rapid Lateral Flow Test for Detecting Neisseria Gonorrhoeae in…NCT07530406 · Not reported · Foundation for Professional Development (Pty) Ltd · starts Sep 11, 2025
- Doxi-Rio: Study on the Use of Doxycycline to Prevent Sexually Transmitted Infections in Rio de JaneiroNCT07500415 · Not applicable · Oswaldo Cruz Foundation · starts Oct 28, 2025
- The Efficacy of Doxycycline Post Exposure Prophylaxis for Preventing STIs Among MSM in Bangkok, Thailand.NCT07397403 · Phase 4 · Bangrak STIs Center · starts Oct 6, 2025
- Improving Maternal and Child Health Through Point-of-care STI TestingNCT07290439 · Not applicable · Emory University · starts Aug 11, 2026
- "Sexual Health Assessment of TinidaZole Against M. Genitalium (SHAZAM)"NCT07088419 · Phase 2 · University of Washington · starts Jul 23, 2025
Approved 7
- CeftriaxoneBacterial penicillin-binding protein inhibitor
- CefiximeBacterial penicillin-binding protein inhibitor
- CiprofloxacinBacterial DNA gyrase inhibitor
- DoxycyclineMatrix metalloproteinase 7 inhibitor
- AmoxicillinBacterial penicillin-binding protein inhibitor
- AmpicillinBacterial penicillin-binding protein inhibitor
- CefotaximeBacterial penicillin-binding protein inhibitor
Phase 3 8
- AzithromycinBacterial 70S ribosome inhibitor
- GepotidacinTopoisomerase IV inhibitor
- ZoliflodacinTopoisomerase IV inhibitor
- Solithromycin
- DelafloxacinBacterial DNA gyrase inhibitor
- GentamicinBacterial 70S ribosome inhibitor
- FosfomycinUDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor
- ErtapenemBacterial penicillin-binding protein inhibitor
Phase 2 3
- AztreonamBacterial penicillin-binding protein inhibitor
- Influenza virus vaccineBiological vaccine - induces immune response
- Thymol
How its trials ended
146 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 37 whose ending is known, 57% met their primary endpoint, 11% missed it and 32% stopped early.
- Completed, result not reported7149%
- Ongoing3323%
- Met its primary endpoint2114%
- Status unknown53%
- Missed its primary endpoint43%
- Stopped: sponsor or business decision43%
- Stopped: other or unclear43%
- Stopped: lack of efficacy21%
- Stopped: enrollment or feasibility21%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA